Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Revvity (RVTY)

Revvity enters $1.5 billion unsecured revolving credit facility maturing January 2030

Neutral Impact 3 of 5 financing Written later

Revvity and its subsidiary Revvity Health Sciences entered a new $1.5 billion unsecured revolving credit facility dated January 7, 2025, with Bank of America as administrative agent. The new facility replaces the prior $1.5 billion facility, which was terminated the same day and had been set to run through August 24, 2026; the new one is available through January 7, 2030. As of January 7, 2025, the borrowers had no borrowings and $4.2 million of letters of credit outstanding.

Key points

  • Facility size of $1.5 billion, available through January 7, 2030
  • Replaces prior $1.5 billion credit agreement dated August 24, 2021, which was terminated January 7, 2025
  • No borrowings and $4.2 million of letters of credit outstanding as of January 7, 2025
  • Interest priced at base rate or term SOFR plus a spread tied to Revvity's credit rating

The filing

CompanyRevvity (RVTY)
Form8-K, current report
Filed with the SECJan 7, 2025, 4:36 PM ET
Accession number0001193125-25-002871

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.